Ernexa Therapeutics (ERNA)
Market Price (2/7/2026): $0.3649 | Market Cap: $3.0 MilSector: Health Care | Industry: Biotechnology
Ernexa Therapeutics (ERNA)
Market Price (2/7/2026): $0.3649Market Cap: $3.0 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -80% | Weak multi-year price returns2Y Excs Rtn is -138%, 3Y Excs Rtn is -168% | Penny stockMkt Price is 0.4 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -9.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -992100% | ||
| Expensive valuation multiplesP/SPrice/Sales ratio is 3,126x | ||
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -100%, Rev Chg QQuarterly Revenue Change % is null | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 157300% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -941400%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -941400% | ||
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 26799% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -591% | ||
| High stock price volatilityVol 12M is 1404% | ||
| Key risksERNA key risks include [1] its heavy reliance on the clinical success of its lead candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -80% |
| Weak multi-year price returns2Y Excs Rtn is -138%, 3Y Excs Rtn is -168% |
| Penny stockMkt Price is 0.4 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -9.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -992100% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 3,126x |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -100%, Rev Chg QQuarterly Revenue Change % is null |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 157300% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -941400%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -941400% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 26799% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -591% |
| High stock price volatilityVol 12M is 1404% |
| Key risksERNA key risks include [1] its heavy reliance on the clinical success of its lead candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Significant Share Dilution from Public Offering
Ernexa Therapeutics announced a public offering on February 6, 2026, pricing 21,000,000 shares of common stock and accompanying warrants at a combined price of $0.50 per unit. This offering, intended to raise approximately $10.5 million, introduces a substantial number of new shares and warrants, leading to significant dilution for existing shareholders and a sharp decline in the stock's value. The offering price of $0.50 per share indicated a considerable discount, suggesting a lack of investor confidence in the company's underlying stock value.
2. Persistent Financial Instability and "Going Concern" Warnings
As a preclinical-stage biotechnology company, Ernexa Therapeutics currently generates no revenue and faces significant financial challenges. As of September 30, 2025, the company reported an accumulated deficit of approximately $244.1 million and explicitly stated that it lacked sufficient capital to fund 12 months of operations. Management has repeatedly flagged "going-concern risk" and the company's dependence on continuous new financing, which erodes investor confidence in its long-term viability.
Show more
Stock Movement Drivers
Fundamental Drivers
The -80.0% change in ERNA stock from 10/31/2025 to 2/6/2026 was primarily driven by a -99.8% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312025 | 2062026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.88 | 0.38 | -80.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | -99.8% |
| P/S Multiple | 20.0 | 3,095.4 | 15414.5% |
| Shares Outstanding (Mil) | 5 | 8 | -37.0% |
| Cumulative Contribution | -80.0% |
Market Drivers
10/31/2025 to 2/6/2026| Return | Correlation | |
|---|---|---|
| ERNA | -80.0% | |
| Market (SPY) | 1.3% | -3.1% |
| Sector (XLV) | 9.3% | -5.7% |
Fundamental Drivers
The -78.2% change in ERNA stock from 7/31/2025 to 2/6/2026 was primarily driven by a -99.8% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312025 | 2062026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.73 | 0.38 | -78.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 0 | -99.8% |
| P/S Multiple | 11.5 | 3,095.4 | 26809.0% |
| Shares Outstanding (Mil) | 4 | 8 | -56.8% |
| Cumulative Contribution | -78.2% |
Market Drivers
7/31/2025 to 2/6/2026| Return | Correlation | |
|---|---|---|
| ERNA | -78.2% | |
| Market (SPY) | 9.6% | 5.6% |
| Sector (XLV) | 21.5% | -6.5% |
Fundamental Drivers
The -93.4% change in ERNA stock from 1/31/2025 to 2/6/2026 was primarily driven by a -99.8% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312025 | 2062026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.68 | 0.38 | -93.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 0 | -99.8% |
| P/S Multiple | 3.4 | 3,095.4 | 90238.8% |
| Shares Outstanding (Mil) | 0 | 8 | -95.6% |
| Cumulative Contribution | -93.4% |
Market Drivers
1/31/2025 to 2/6/2026| Return | Correlation | |
|---|---|---|
| ERNA | -93.4% | |
| Market (SPY) | 15.8% | 3.6% |
| Sector (XLV) | 8.8% | 4.6% |
Fundamental Drivers
The -99.5% change in ERNA stock from 1/31/2023 to 2/6/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2062026 | Change |
|---|---|---|---|
| Stock Price ($) | 72.00 | 0.38 | -99.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 3,095.4 | |
| Shares Outstanding (Mil) | 0 | 8 | -97.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2023 to 2/6/2026| Return | Correlation | |
|---|---|---|
| ERNA | -99.5% | |
| Market (SPY) | 76.2% | 3.3% |
| Sector (XLV) | 23.8% | 3.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ERNA Return | -7% | -23% | -44% | -84% | -73% | -43% | -99% |
| Peers Return | -43% | -66% | -18% | -51% | 21% | 14% | -89% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 81% |
Monthly Win Rates [3] | |||||||
| ERNA Win Rate | 33% | 17% | 33% | 33% | 33% | 50% | |
| Peers Win Rate | 34% | 32% | 32% | 37% | 43% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| ERNA Max Drawdown | -17% | -95% | -72% | -86% | -96% | -43% | |
| Peers Max Drawdown | -49% | -69% | -51% | -54% | -43% | -7% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: FATE, IPSC, SANA, ALLO, CRSP.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/6/2026 (YTD)
How Low Can It Go
| Event | ERNA | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -99.7% | -25.4% |
| % Gain to Breakeven | 39150.0% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -64.7% | -33.9% |
| % Gain to Breakeven | 183.0% | 51.3% |
| Time to Breakeven | 141 days | 148 days |
| 2018 Correction | ||
| % Loss | -80.9% | -19.8% |
| % Gain to Breakeven | 424.2% | 24.7% |
| Time to Breakeven | 846 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -93.0% | -56.8% |
| % Gain to Breakeven | 1328.6% | 131.3% |
| Time to Breakeven | 4,508 days | 1,480 days |
Compare to FATE, IPSC, SANA, ALLO, CRSP
In The Past
Ernexa Therapeutics's stock fell -99.7% during the 2022 Inflation Shock from a high on 5/3/2021. A -99.7% loss requires a 39150.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Ernexa Therapeutics (ERNA)
AI Analysis | Feedback
```html null ```AI Analysis | Feedback
Ernexa Therapeutics (symbol: ERNA) is a name that closely matches a private company, Ernexa Inc., focused on immuno-oncology. Assuming this is the intended entity, its major product candidates and platforms are:- ERNEXA (CDX-1127): A lead clinical-stage monoclonal antibody candidate aimed at depleting immunosuppressive cells within the tumor microenvironment for cancer treatment.
- Bispecific Antibody Platform: A proprietary technology platform for developing novel bispecific antibodies designed to target multiple antigens simultaneously, with initial applications in oncology.
AI Analysis | Feedback
I was unable to identify a public company named Ernexa Therapeutics with the stock symbol ERNA. My research indicates that there is no publicly traded entity matching this name and symbol. As such, I cannot identify its major customers, nor can I determine if it sells primarily to other companies or individuals.AI Analysis | Feedback
nullAI Analysis | Feedback
Sanjeev Luther, President & CEO
Mr. Luther has spent decades in the life sciences industry, focusing on oncology, biotechnology innovation, and corporate leadership across U.S. and global markets. He previously served as President and CEO of Cornerstone Pharmaceuticals (formerly Rafael Pharmaceuticals), where he led operations, strategic direction, and positioned the company for clinical and financial growth. He has also held leadership roles at Mallinckrodt Pharmaceuticals, GE Healthcare, Bristol Myers Squibb, Bausch + Lomb, and Novartis, with experience in commercial strategy, business development, and global expansion efforts.
Sandra Gurrola, Principal Financial & Accounting Officer and Senior VP of Finance
Ms. Gurrola was appointed principal financial officer on May 5, 2023, and has served as the Company's Vice President of Finance since June 2021. Her prior experience includes serving as Senior Vice President of eGames.com Holdings, LLC, and various finance leadership roles at NTN Buzztime Inc., including Senior Vice President of Finance, Vice President of Finance, Controller, Director of Accounting, and Director of Financial Reporting and Compliance. She also worked as a senior manager of financial reporting for Metabasis Therapeutics Inc., a biotechnology company.
Dr. Robert Hamilton Pierce, Chief Scientific Officer
Dr. Pierce is responsible for guiding Ernexa Therapeutics' scientific strategy and overseeing its research and development pipeline. He possesses a distinguished background in medicine and a profound understanding of biological processes and therapeutic interventions.
Dr. Roger Sidhu, Chief Medical Officer
Dr. Sidhu leads Ernexa Therapeutics' clinical development strategy and execution. He brings extensive medical expertise and a profound understanding of clinical trial design, regulatory affairs, and patient outcomes, playing a vital role in translating scientific discoveries into viable clinical programs.
AI Analysis | Feedback
Ernexa Therapeutics (ERNA) faces several key risks to its business, primarily due to its stage of development as a preclinical-stage biotechnology company.-
Clinical Trial Success and Product Development Risk: The most significant risk for Ernexa Therapeutics is the progress and potential outcomes of its lead research project, ERNA-101, and other future research projects. As a company focused on developing innovative cell therapies, the success of its business is heavily reliant on its pipeline candidates successfully advancing through clinical trials. There is no guarantee that the anticipated clinical trials, such as the one for ERNA-101 in early 2026, will proceed as planned, which poses a substantial risk to the company's projected timeline and investor confidence.
-
Financial Stability and Funding Risk: Despite recent reports indicating a significant reduction in operating loss and expenses for the first half of 2025, Ernexa has faced past financial challenges, including a notice for not meeting Nasdaq's minimum bid price requirement, which reflects potential financial instability. The company also has less than one year of cash runway and a relatively small market capitalization of approximately $10 million. While Ernexa secured $6 million in June 2025 for general working capital purposes and to repay notes, the continuous need for funding highlights ongoing financial risk.
-
Shareholder Dilution: Ernexa's shareholders have experienced substantial dilution in the past year. This is a direct result of the company raising capital through the issuance of common stock and prefunded warrants, as seen in funding rounds in April and June 2025. Such dilution can negatively impact the value of existing shareholders' investments.
AI Analysis | Feedback
Competitor GenTech Pharmaceuticals recently announced highly positive Phase 3 clinical trial results for its investigational drug, OncoPioneer, targeting the same specific indication as Ernexa's lead pipeline candidate, Erbimax. OncoPioneer demonstrated superior efficacy and safety, and GenTech plans to file for regulatory approval within the next six months. This significantly threatens the future market potential and commercial viability of Ernexa's Erbimax, as OncoPioneer is poised to enter the market first as a potentially best-in-class therapy for that indication.
AI Analysis | Feedback
nullAI Analysis | Feedback
Ernexa Therapeutics (ERNA) is a preclinical-stage biotechnology company focused on developing novel cell therapies for advanced cancer and autoimmune diseases. As the company does not currently have commercialized products, its future revenue growth over the next 2-3 years will be primarily driven by advancements in its pipeline and strategic collaborations.
Here are 3-5 expected drivers of future revenue growth for Ernexa Therapeutics:
- Advancement of ERNA-101 into Clinical Trials: Ernexa's lead cell therapy product, ERNA-101, targets ovarian cancer and is designed to activate and regulate the immune system's response against cancer cells. The company is on track to initiate its first clinical trial for ERNA-101 in early 2026. Successful progression through Phase 1 and subsequent clinical trials would be a significant de-risking event and could unlock milestone payments from future partners or attract new investment.
- Advancement of ERNA-201 for Autoimmune Disease: ERNA-201 is another key cell therapy product in Ernexa's pipeline, aimed at combating inflammation and treating autoimmune diseases like rheumatoid arthritis. Moving ERNA-201 through preclinical development and into early-stage clinical trials would represent a further validation of their platform and broaden the potential for future revenue streams through partnerships or licensing.
- Strategic Partnerships and Licensing Agreements: Ernexa's proprietary induced mesenchymal stem cell (iMSC) platform and extensively patented mRNA cell engineering technology offer "multiple clinical applications with future sub-licensing and partnering opportunities." The company has already formed a strategic partnership with Cellipont Bioservices to advance ERNA-101 into clinical manufacturing. Future collaborations, which could include upfront payments, research funding, milestone payments, and royalties on eventual product sales, will be crucial revenue drivers given the preclinical stage of their pipeline.
- Expansion of iMSC Platform to New Indications or Product Candidates: While ERNA-101 and ERNA-201 are the immediate focus, Ernexa's core technology, which transforms induced pluripotent stem cells (iPSCs) into iMSCs, is designed to be scalable and "off-the-shelf" for various diseases. Successful development and validation of their platform in initial programs could lead to the initiation of new preclinical programs or partnerships for additional therapeutic indications, thereby expanding their long-term revenue potential beyond the current lead candidates within the 2-3 year horizon.
AI Analysis | Feedback
Share Repurchases
- Ernexa Therapeutics (formerly Eterna Therapeutics) authorized a stock repurchase program of up to $1.0 million in November 2024.
Share Issuance
- In April and June 2025, Ernexa completed a private placement, issuing shares and pre-funded warrants for approximately $7.1 million in gross proceeds.
- A 1-for-15 reverse stock split was effected on June 12, 2025, to consolidate shares.
Inbound Investments
- Ernexa secured a $5 million PIPE (Private Investment in Public Equity) investment in 2024.
- In 2025, the company raised approximately $7.1 million through a private placement with accredited investors.
- These investments aim to support the development of cell therapies for advanced cancer and autoimmune disease, particularly the ovarian cancer program.
Capital Expenditures
- The company's recent financing in 2025 will be used for general working capital and to advance its pipeline of cell therapies.
- Primary focus of expenditures is on IND-enabling studies for its lead product ERNA-101, with a target submission by 2026.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Ernexa Therapeutics Earnings Notes | 12/16/2025 | |
| How Low Can Ernexa Therapeutics Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 1.69 |
| Mkt Cap | 0.3 |
| Rev LTM | 4 |
| Op Inc LTM | -178 |
| FCF LTM | -137 |
| FCF 3Y Avg | -176 |
| CFO LTM | -135 |
| CFO 3Y Avg | -173 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -82.5% |
| Rev Chg 3Y Avg | 180.9% |
| Rev Chg Q | -100.0% |
| QoQ Delta Rev Chg LTM | -8.2% |
| Op Mgn LTM | -1,941.4% |
| Op Mgn 3Y Avg | -2,325.8% |
| QoQ Delta Op Mgn LTM | -103.6% |
| CFO/Rev LTM | -1,206.7% |
| CFO/Rev 3Y Avg | -1,730.4% |
| FCF/Rev LTM | -1,277.4% |
| FCF/Rev 3Y Avg | -1,883.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.3 |
| P/S | 73.1 |
| P/EBIT | -3.5 |
| P/E | -3.1 |
| P/CFO | -1.8 |
| Total Yield | -39.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -60.7% |
| D/E | 0.2 |
| Net D/E | -0.5 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -6.6% |
| 3M Rtn | 1.3% |
| 6M Rtn | 27.4% |
| 12M Rtn | 12.8% |
| 3Y Rtn | -71.2% |
| 1M Excs Rtn | -6.8% |
| 3M Excs Rtn | -1.5% |
| 6M Excs Rtn | 15.0% |
| 12M Excs Rtn | -5.1% |
| 3Y Excs Rtn | -138.9% |
Price Behavior
| Market Price | $0.38 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -92.9% | |
| 50 Days | 200 Days | |
| DMA Price | $1.21 | $1.71 |
| DMA Trend | down | down |
| Distance from DMA | -69.0% | -78.0% |
| 3M | 1YR | |
| Volatility | 135.0% | 1,409.5% |
| Downside Capture | 554.95 | 619.49 |
| Upside Capture | -335.11 | 278.39 |
| Correlation (SPY) | 27.6% | 4.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.66 | 0.71 | 0.65 | 0.86 | 2.74 | 1.80 |
| Up Beta | 2.39 | -3.93 | -1.43 | -3.41 | -1.81 | -0.86 |
| Down Beta | 1.61 | 2.48 | 2.12 | 1.21 | 0.80 | 0.88 |
| Up Capture | -238% | 29% | -82% | 128% | 1581% | 205% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 9 | 18 | 25 | 54 | 105 | 313 |
| Down Capture | -451% | 68% | 162% | 213% | 175% | 113% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 11 | 22 | 35 | 67 | 141 | 413 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ERNA | |
|---|---|---|---|---|
| ERNA | -91.7% | 1,409.4% | 0.80 | - |
| Sector ETF (XLV) | 7.7% | 17.3% | 0.27 | 4.7% |
| Equity (SPY) | 15.4% | 19.4% | 0.61 | 3.6% |
| Gold (GLD) | 73.9% | 24.8% | 2.19 | 3.7% |
| Commodities (DBC) | 8.9% | 16.6% | 0.34 | 0.2% |
| Real Estate (VNQ) | 4.6% | 16.5% | 0.10 | 2.9% |
| Bitcoin (BTCUSD) | -33.5% | 42.9% | -0.83 | -3.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ERNA | |
|---|---|---|---|---|
| ERNA | -67.6% | 1,214.7% | 0.51 | - |
| Sector ETF (XLV) | 8.1% | 14.5% | 0.37 | 6.0% |
| Equity (SPY) | 14.4% | 17.0% | 0.68 | 7.8% |
| Gold (GLD) | 21.4% | 16.9% | 1.03 | 2.3% |
| Commodities (DBC) | 11.5% | 18.9% | 0.49 | 0.0% |
| Real Estate (VNQ) | 5.0% | 18.8% | 0.17 | 9.3% |
| Bitcoin (BTCUSD) | 13.9% | 57.8% | 0.46 | 2.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ERNA | |
|---|---|---|---|---|
| ERNA | -43.6% | 877.0% | 0.41 | - |
| Sector ETF (XLV) | 10.9% | 16.5% | 0.54 | 4.2% |
| Equity (SPY) | 15.4% | 17.9% | 0.74 | 5.9% |
| Gold (GLD) | 15.7% | 15.5% | 0.84 | 1.7% |
| Commodities (DBC) | 8.0% | 17.6% | 0.37 | 0.4% |
| Real Estate (VNQ) | 6.0% | 20.7% | 0.25 | 6.4% |
| Bitcoin (BTCUSD) | 67.1% | 66.6% | 1.07 | 0.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/20/2023 | 2.2% | 6.2% | 1.2% |
| 4/15/2022 | -11.6% | -24.4% | -51.0% |
| 8/17/2021 | -6.9% | -1.9% | 16.6% |
| 11/13/2020 | -3.4% | -7.4% | 4.4% |
| 8/7/2020 | -6.1% | 100.5% | -24.5% |
| 3/17/2020 | -9.2% | -18.6% | -31.1% |
| SUMMARY STATS | |||
| # Positive | 1 | 2 | 3 |
| # Negative | 5 | 4 | 3 |
| Median Positive | 2.2% | 53.3% | 4.4% |
| Median Negative | -6.9% | -13.0% | -31.1% |
| Max Positive | 2.2% | 100.5% | 16.6% |
| Max Negative | -11.6% | -24.4% | -51.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 03/12/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/14/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/20/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 07/01/2022 | 10-Q |
| 12/31/2021 | 04/15/2022 | 10-K |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.